NEW YORK (GenomeWeb News) – The Burzynski Research Institute has struck a research agreement with the University of Alabama at Birmingham, under which the school will provide bioinformatics and data management support for the company's glioma treatment studies.
BRI, a Houston-based company focused on using genomics and epigenomics for cancer studies, said that UAB's Biostatistics and Bioinformatics Shared Facility (BBSF) will support its Phase I and Phase II protocol studies of Antineoplaston therapy, a treatment for gliomas.
BBSF will support BRI's statistical analysis development in a variety of ways, including database design, data receipt, management, long-term storage, implementing quality assurance plans, and data quality and reporting. The facility is developing new methodologies and approaches for incorporating the results of statistical analyses into reports, presentations, and publications, and systems for long-term data storage, backup, and retrieval.
BBSF already has helped BRI develop Phase II and Phase III protocol studies of Antineoplaston therapy for glioma, which is currently being submitted to the US Food and Drug Administration for approval, the company said.